34
Participants
Start Date
January 28, 2022
Primary Completion Date
January 2, 2024
Study Completion Date
January 2, 2024
agenT-797
agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Approved ICIs
Nivolumab and pembrolizumab
Sarah Cannon Research Institute, Nashville
Norton Cancer Health, Louisville
University of Cincinnati Cancer Center, Cincinnati
University of Colorado, Aurora
University of Southern California, Los Angeles
Providence Portland Medical Center, Portland
Beth Israel Deaconess Medical Center, Boston
LifeSpan - Rhode Island Hospital, Providence
Lead Sponsor
MiNK Therapeutics
INDUSTRY